A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer.
about
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical StatusDesign and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA).Synthesis and evaluation of [64Cu]PSMA-617 targeted for prostate-specific membrane antigen in prostate cancerClinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer.The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.PET imaging in prostate cancer: focus on prostate-specific membrane antigen⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer.(68)Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological diseaseMetal-Based PSMA Radioligands.Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer.Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate CancerClinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer.Synthesis and evaluation of 68 Ga-HBED-CC-EDBE-folate for positron-emission tomography imaging of overexpressed folate receptors on CT26 tumor cells.Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.Unusual Uptake of Prostate Specific Tracer 68Ga-PSMA-HBED-CC in a Benign Thyroid Nodule.Development of a Single Vial Kit Solution for Radiolabeling of 68Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients.Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer.(68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging?Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer.PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study)
P2860
Q26774920-C2D746D5-5B60-40E1-BF70-ADBE5572AFF9Q33586706-21C6CAB9-2102-421C-B1B1-111F6CD001F1Q33700114-7EE2928D-A87B-402A-88FC-651C891F83DDQ33711641-C30BCA09-E869-49FB-B02C-16B4D85FAF11Q35043569-907F4262-2F84-4DD6-AB1D-16D93E143087Q36942136-C256F5DC-B9B3-4F88-ADE3-C99A59254431Q37350456-EE21AFEA-CB29-4470-8874-6D5C224B635FQ38099369-0CB06056-16CA-4E86-988D-905122DCC899Q38705627-6BF1FF82-BA37-4A9B-9A26-0542C527892AQ38747415-9DEC55B0-1AAC-4277-8095-7C44CC791200Q38831232-CDB06B4D-04DE-4D68-8DFB-5CAD205BE247Q39198527-08074FF7-194C-478F-8113-E973B038DF64Q39690658-7E32CF54-D5C7-47C2-A986-7BF61FC85093Q39710843-9AAA7071-126A-47C3-BDEA-21E2088ABEA9Q41319390-F6134267-7E91-4A59-84E2-30C0D6CF9E40Q41905456-AF8869E7-53DE-4D96-8759-271232E0CB0EQ46729784-15702897-63C6-4731-BE57-20106B8CF8D5Q48054086-A600B38E-B90B-4270-8EDD-319047C15671Q48189196-91897A49-9C8F-4BE2-BEBA-4832F4C7BCE1Q48295687-C8722993-7C3D-4CF3-915F-9E9D94524033Q48905216-174B8021-8186-4E58-9252-E9042852E611Q50285831-5F99C37A-8BEA-4AE2-94FE-55B6D38E932DQ51803631-8D729239-A26D-49B3-9315-377D738041AAQ52982825-93892CB6-97A1-4A6E-8702-F668A5E1D7F4Q52985772-577BD08A-CE9A-428A-B4F5-4074F08F065EQ53059256-F258783F-38A8-4103-82FF-E8D90FA12B5CQ53070213-8197F210-9D71-4900-85E4-86939217A488Q53131398-3AB774B9-F5BA-4FE9-81E5-EAE296AAC12CQ57815798-1D072A6E-2A0A-4E42-879A-38391DB0F39A
P2860
A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A dimerized urea-based inhibit ...... ET imaging of prostate cancer.
@en
type
label
A dimerized urea-based inhibit ...... ET imaging of prostate cancer.
@en
prefLabel
A dimerized urea-based inhibit ...... ET imaging of prostate cancer.
@en
P2093
P2860
P356
P1433
P1476
A dimerized urea-based inhibit ...... ET imaging of prostate cancer.
@en
P2093
Frederic Zoller
Karin Leotta
Martin Schäfer
Matthias Eder
Michael Eisenhut
Ulrike Bauder-Wüst
Uwe Haberkorn
P2860
P2888
P356
10.1186/2191-219X-2-23
P50
P577
2012-06-06T00:00:00Z
P6179
1034937653